The genomics company said the organizational change will eventually reduce annual payroll and benefit expenses by $12.8 million, per the June 9 filing. The reduction plan is expected to be completed by the first quarter of fiscal 2024, which ends March 31. 23andMe’s net losses increased from $217 million to $317 million in the 12 months ending in March, according to a May earnings report.
“As we continue to navigate uncertainties in the global economy and financial markets, we made the difficult decision to reduce our workforce by 9 percent,” a company spokesperson emailed Becker’s. “We believe this will help ensure 23andMe is set up for long-term growth and success. Those impacted have been notified, and we are truly grateful for their part in helping grow our business and delivering on our mission.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
